Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ParvOryx in metastatic, inoperable pancreatic cancer (Phase II, single-arm)
2015-001119-11Phase 2Completed
- Sponsor
- Oryx GmbH & Co KG
- Start
- Apr 2015
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ParvOryx in pancreatic cancer (PC), sponsored by Oryx GmbH & Co KG. Primary endpoint: Extent of metastatic necrosis and other pathological characteristics. Started Apr 2015; status: completed.
02
Drugs
ParvOryx
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2015-001119-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001119-11.